Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2018

Motea Edward A, Fattah Farjana J, Xiao Ling, Girard Luc, Rommel Amy, Morales Julio C, Patidar Praveen, Zhou Yunyun, Porter Andrew, Xie Yang, Minna John D, Boothman David A

Abstract excerpt

PURPOSE: Identification of novel strategies to expand the use of PARP inhibitors beyond BRCA deficiency is of great interest in personalized medicine. Here, we investigated the unannotated role of Kub5-HeraRPRD1B (K-H) in homologous recombination (HR) repair and its potential clinical significance in targeted cancer therapy. EXPERIMENTAL DESIGN: Functional characterization of K-H alterations on HR repair of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CDC2 Protein Kinase
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Genes, Reporter

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Synthetic Lethal Mutations

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 30108102
DOI: 10.1158/1078-0432.CCR-17-1118
PMCID: PMC6295248

Genes

BRCA1
CDK1
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.PMID 30108102Read ↗

Beyond BRCA: Discovery of novel causes and consequences of homologous recombination deficienciesSemantic proximity Read ↗

Mutational and functional heterogeneity of homology-directed repair deficiency and clinical implicationsSemantic proximity Read ↗

Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Semantic proximity Read ↗

Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and CancerSemantic proximity Read ↗

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.Semantic proximity Read ↗

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaSemantic proximity Read ↗

Homologous recombination in cancer development, treatment and development of drug resistanceSemantic proximity Read ↗

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read ↗

Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2Semantic proximity Read ↗

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity Read ↗

Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancerSemantic proximity Read ↗

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.